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Abstract
Novel therapies are undergoing clinical trials, for example, the
Hsp90 inhibitor, XL888, in combination with BRAF inhibitors for
the treatment of therapy-resistant melanomas. Unfortunately, our
data show that this combination elicits a heterogeneous response
in a panel of melanoma cell lines including PDX-derived models.
We sought to understand the mechanisms underlying the differen-
tial responses and suggest a patient stratification strategy. Ther-
mal proteome profiling (TPP) identified the protein targets of
XL888 in a pair of sensitive and unresponsive cell lines. Unbiased
proteomics and phosphoproteomics analyses identified CDK2 as a
driver of resistance to both BRAF and Hsp90 inhibitors and its
expression is regulated by the transcription factor MITF upon
XL888 treatment. The CDK2 inhibitor, dinaciclib, attenuated resis-
tance to both classes of inhibitors and combinations thereof.
Notably, we found that MITF expression correlates with CDK2
upregulation in patients; thus, dinaciclib would warrant considera-
tion for treatment of patients unresponsive to BRAF-MEK and/or
Hsp90 inhibitors and/or harboring MITF amplification/overexpres-
sion.
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Introduction
Malignant melanoma has the highest somatic mutational rate
among cancers (Alexandrov et al, 2013) and its incidence is steadily
increasing (https://training.seer.cancer.gov/melanoma/intro/). In
the majority of the cases, it harbors BRAF (~60%) or NRAS (~20%)
mutation. Other notable genomics alterations include the tumor
suppressor CDNK2A deletions, KIT aberrations, MITF amplifications
(10–20%), PIK3 mutations, loss of NF1 (Whittaker et al, 2013) and
PTEN deletions (Chin et al, 2006).
The introduction of BRAF inhibitors (BRAFi), such as vemu-
rafenib and dabrafenib, as standard of care for the treatment of
BRAF-mutant melanoma has significantly improved the response
rate among patients (Chapman et al, 2011). However, the benefits
from BRAFi monotherapy are only temporary, as after ~6 months
the majority of the patients experience tumor progression. Drug
resistance results from a plethora of mechanisms, both MAPK-
dependent and MAPK-independent. For example, several mutations
in the MAPK pathway have been detected in BRAFi-resistant cell
lines or patients’ tumors, such as activating mutations in MEK1/2
(Wagle et al, 2014) and in NRAS (~21%; Nazarian et al, 2010; Shi
et al, 2014). Resistance can proceed through switching between
RAF isoforms, expression of alternative RAF splice variants
(Poulikakos et al, 2011), alternative BRAF protein with a duplicated
kinase domain (Kemper et al, 2016), or overexpression of CRAF
(Montagut et al, 2008) or COT (Johannessen et al, 2010). MAPK-
independent mechanisms have also been observed, such as upregu-
lation of compensatory receptor tyrosine kinases, for example,
PDGFRb (Nazarian et al, 2010), IGF-1R (Villanueva et al, 2010) or
EGFR (Girotti et al, 2013).
In 2011, the Food and Drug Administration approved the use of
immunotherapy for the treatment of metastatic melanoma. The
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response rate of patients treated with immunotherapy is generally
lower than targeted therapy (10–40% versus ~60%), although the
clinical benefit of immunotherapy is often more stable (~2 years)
and patients with tumors lacking BRAF mutations can also benefit
from such treatment (Flaherty et al, 2010; Topalian et al, 2012;
Johnson & Puzanov, 2015). Unfortunately, one of the main side
effects of immunotherapy is the development of immune-related
adverse events, which in some cases can be fatal. Thus, there is an
urgent need for new drug strategies that would prevent the develop-
ment of melanoma resistance to targeted therapies and would be
suitable for patients that are inherently unresponsive to targeted- or
immunotherapies currently in clinical use.
One such strategy to attenuate the development of resistance is
the use of combinations of drugs (Al-Lazikani et al, 2012). A
number of combination therapies are undergoing clinical trials and
have been reported to overcome melanoma primary/acquired resis-
tance to drug treatments, such as Hsp90 inhibitors (Hsp90i; e.g.,
XL888; Phadke et al, 2015). In this particular case, the underlying
rationale is to inhibit the chaperone activity of Hsp90, which assists
in the folding of several oncoproteins, such as AKT, CDK4, COT,
ERBB2/3, FYN, or CRAF (Taipale et al, 2012), whose upregulation
underlies the onset of resistance (Paraiso et al, 2012). Hsp90i have
been reported to overcome acquired resistance to BRAF and
MEK inhibitors in melanoma cell lines (Smyth et al, 2014). The
combined therapies vemurafenib-XL888 (Paraiso et al, 2012;
NCT01657591) and the recent triple combination BRAFi-MEKi-XL888
(NCT02721459) are currently being tested in clinical trials in
patients with melanoma harboring BRAF mutations. To date, a set
of protein biomarkers that would enable monitoring of patient
response and distinguish between responders and non-responders
to these combined therapies is not available. The only attempt to
generate such a shortlist of potential biomarkers was performed by
Rebecca et al (2014) on BRAF- or NRAS-mutated responsive cell
lines/patient specimens.
Importantly, when we assayed cell viability on a panel of mela-
noma cell lines that included PDX-derived disease models, a subset
was unresponsive to Hsp90i, pointing to an urgent need for patient
stratification strategies. To make matters worse, the spectrum of
molecular (off-) targets of Hsp90i has not been thoroughly investi-
gated. The off-targets might cause a paradoxical activation of mech-
anisms of resistance to the drug therapy as was shown previously
for the BRAFi PLX4032 (Poulikakos et al, 2010).
In this study, we aimed at providing a systems-level understand-
ing of the differential response to BRAFi and Hsp90i classes of inhi-
bitors and their combinations in sensitive and non-responsive cell
lines. We employed a thermal proteome profiling (TPP) approach to
investigate the protein targets of the Hsp90i XL888 in sensitive and
resistant cell lines and tease apart their eventual differences in terms
of drug targets so as to provide insight into the mechanisms of resis-
tance to XL888. In parallel, we employed orthogonal unbiased proteo-
mics and phosphoproteomics approaches, which offer a systems-level
understanding of the cell signaling pathways that contribute to the
inherent unresponsiveness to Hsp90i and BRAFi classes. The results
provided by these complementary approaches enabled us to design
drug strategies to overcome melanoma resistance to both BRAFi and
Hsp90i monotherapies and their combination. Our in vitro findings
would warrant consideration for more in-depth in vivo studies.
Results
Heterogeneous response to BRAFi and Hsp90i in a panel of
melanoma cell lines
Given the current clinical trials testing BRAFi and Hsp90i, we sought
to identify a drug therapy that would overcome both BRAFi and
Hsp90i inherent resistance simultaneously. In order to understand
factors influencing drug response to the single treatments, we first
assessed the cell viability with an MTS assay upon treatment with
dabrafenib in a panel of BRAF-mutant melanoma cell lines that
included patient-derived xenografts (PDX) collected before treat-
ment with vemurafenib (M026.X1.CL) and after the onset of resis-
tance due to an acquired NRAS mutation (M026R.X1.CL; Possik
et al, 2014; Kemper et al, 2016). Six out of nine cell lines were resis-
tant to dabrafenib: three were inherently unresponsive (SK-Mel 24,
SK-Mel 28, and ESTDAB037), whilst three were unresponsive due to
acquired resistance developed either in vitro (A375 DR1 and MNT-1
DR100) or in vivo (M026R.X1.CL; Fig 1A).
Next, in the same panel we assessed the cell viability following
XL888 treatment and investigated whether any resistant cell line
might be inherently unresponsive to this Hsp90i currently used in
clinical trials to treat melanoma (NCT01657591). Interestingly,
XL888 drastically reduced the viability in the previously unrespon-
sive SK-Mel 24 cells, but not in SK-Mel 28, or in cells with acquired
resistance to BRAFi (M026R.X1.CL, MNT-1 DR100, A375 DR1;
Fig 1B). Notably, the parental cell lines A375 and MNT-1 (which are
sensitive to BRAFi) did not respond to XL888 treatment.
Since SK-Mel 24 and SK-Mel 28 were both unresponsive to
BRAFi, but showed differential apoptotic response to BRAFi-XL888
combined therapy or XL888 monotherapy (Fig 1C), we decided to
further investigate the underlying differences between these two cell
lines.
▸Figure 1. Different cell responses upon treatment with BRAF and Hsp90 inhibitors.A Cell viability measured on a panel of melanoma cells upon 72-h treatment with dabrafenib (BRAFi) (SD is plotted; n = 3).
B Cell viability measured on a panel of melanoma cells upon 72-h treatment with XL888 (Hsp90i) (SD is plotted; n = 3).
C Analysis of apoptotic cells in SK-Mel 24 and SK-Mel 28 by annexin V after 72-h treatment with BRAFi (1 lM dabrafenib) or Hsp90i (200 nM XL888) alone and BRAFi
(1 lM dabrafenib) and Hsp90i (200 nM XL888) combined treatment (SD is plotted; n = 3).
D Cell viability for SK-Mel 28 (left panel) and SK-Mel 24 (right panel) was measured after 72-h treatment with other Hsp90 inhibitors (aside from XL888), such as
AUY022, BIIB021, novobiocin, and 17-DMAG. (Discrepancies in the concentration–response profiles for SK-Mel 28 to XL888 between (B and D) can be attributed to the
viability surrogate that is measured. In the case of (B), the MTS assay, quantifying metabolic activity, is used, whereas (D) is based on readout of ATP using CellTiter-
Glo. In both assays, incomplete killing occurs at the concentrations of drugs used) (SD is plotted; n = 3).
E ZIP model to evaluate the combined effect BRAFi and Hsp90i in SK-Mel 28 (SD is plotted; n = 3).
F ZIP model to evaluate the combined effect BRAFi and Hsp90i in SK-Mel 24 (SD is plotted; n = 3).
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In order to determine whether the cell lines were unresponsive to
XL888 specifically or to Hsp90i in general, SK-Mel 28 and SK-Mel 24
were treated with a panel of Hsp90i (including AUY022, BIIB021,
novobiocin, and 17-DMAG) and ATP levels were measured as a
surrogate for cell viability. Our results indicate that treatment with
the Hsp90i panel, with the exception of novobiocin, yielded complete
loss of viability in SK-Mel 24 (Fig 1D, right panel), while in SK-Mel
28 the viability was only partially reduced (Fig 1D, left panel).
To understand the results from the combined treatment (1 lM
dabrafenib plus 200 nM XL888 from Fig 1C), we performed full
isobologram treatment of dabrafenib and XL888 in the differentially
responsive cell lines, SK-Mel 28 and SK-Mel 24. A zero interaction
potency (ZIP) model was used to interpret the results (Yadav et al,
2015), revealing that in SK-Mel 28 an antagonistic response is
observed for some of the concentrations of XL888 combined with
dabrafenib (Fig 1E; e.g., 1 lM dabrafenib plus 200 nM XL888), indi-
cating that the cell viability is affected to a lesser extent as compared
to monotherapy for this cell line. In SK-Mel 24 cells, however, a
synergistic effect is detected in the combined treatment (Fig 1F).
Overall, these melanoma cell lines, while being inherently resistant
to BRAFi, responded heterogeneously to both Hsp90i monotherapy
and the combined treatment BRAFi-Hsp90i. The results highlight the
urgent need for patient stratification strategies for monotherapies
with BRAFi and Hsp90i and their combination, especially when
antagonism between the two drugs is observed in some cases.
TPP and phospho-TPP reveal different protein targets of the
Hsp90i XL888 in sensitive and unresponsive cells
To elucidate the mechanisms underlying a differential response of
melanoma cells to BRAFi, Hsp90i, and their combined treatment,
we employed a multifaceted proteomics approach. We first investi-
gated the binding partners of XL888 in SK-Mel 24 and SK-Mel 28
cells using thermal proteome profiling (TPP; Martinez Molina et al,
2013; Savitski et al, 2014). We performed TPP in lysate and in intact
cells with and without XL888 treatment for the two cell lines
(Fig EV1A–C). The TPP experiments and analyses are summarized
in Table 1 and Fig EV1D (Dataset EV1).
Here, we found that Hsp90 and GLUD2 are the main targets
shared between SK-Mel 24 and 28 from the two experimental
layouts (drug/DMSO). Overall, the two cell lines show poor overlap
in terms of drug–protein engagement. Regarding the (few) shared
entries in the intact cell layout (drug/DMSO), we observed stabiliza-
tion of the chaperone CDC37, a known Hsp90 interactor (Taipale
et al, 2014; Dataset EV1, Fig EV1E).
Moreover, for the first time, we performed the analysis of the
thermal stability of the phosphoproteome in intact cells, providing a
snapshot of the cell signaling response due to the drug treatment
perturbation. Here, we observed higher thermal stability of phos-
phorylated CRAF (pS301) in SK-Mel 28 (drug/DMSO; Dataset EV1).
Importantly, aside from comparing treated versus control samples
in different layouts, it is also possible to investigate the eventual inher-
ent differences of the proteome and phosphoproteome thermal stabil-
ity of sensitive and unresponsive cell lines to gain insight into the
signaling pathways that underlie the resistance of SK-Mel 28 to Hsp90i
(Fig EV1F). Overall, we built an interaction map based on the statisti-
cally significant proteins/phosphoproteins (Figs EV2 and EV3).
Considering the “druggability” of the kinome, we focused our
attention on protein kinases with differential thermal stability between
SK-Mel 28 versus SK-Mel 24 cells using the cell extract layout. The
comparison revealed differences among regulators of cell cycle
progression, for example, CDK2, CDK4, CDK6, and PAK2, highlighting
these proteins as potential targets to overcome the inherent resistance
of SK-Mel 28 (Fig EV4A). The higher thermal stability of CDK6 was
observed also in the intact cells layout (Dataset EV1).
Notably, when comparing the phosphoproteome thermal stability
of the two cell lines, we observed higher stability in SK-Mel 28 of
the protein regulator of cell proliferation pPAK4 (S474; which regu-
lates the expression of the transcription factor MITF, responsible for
melanocyte differentiation; Yun et al, 2015), and the transcription
factor pSTAT1 (S727; Fig EV4A). The higher thermal stability of the
(active) kinase pPAK4 (S474) was also confirmed by Western blot
(Fig EV4B). This suggests that the active state of these two phospho-
rylated proteins might be more stable in the resistant cells due to
additional post-translational modifications.
Overall, the different comparisons of the (phospho)proteome
thermal stability of resistant versus sensitive cells in different
settings using TTP identified six potential targets, whose inhibition
could sensitize the resistant cells to XL888 (henceforth referred as
Hsp90i): CDK2, CDK4, CDK6, CRAF, PAK2, PAK4, and STAT1.
Proteomics and phosphoproteomics analyses reveal that primary
resistance to BRAFi is accompanied by MAPK pathway activation
As a complementary approach to strengthen the initial hypotheses
gained from TPP, we employed an unbiased genomewide proteo-
mics and phosphoproteomics platform to address a number of rele-
vant biological questions in SK-Mel 24 and SK-Mel 28. This
provided insight into changes of the membrane proteome that may
have been missed using TPP. Cell lines that were sensitive (SK-Mel
24) or unresponsive (SK-Mel 28) to XL888 treatments were grown
under conditions as detailed in Fig 2A for 48 h, lysed, and the
lysates digested by Lys-C/trypsin. Protein quantification was
performed using a label-free approach. The same workflow was
Table 1. Results of the TPP investigations in different settings.
TPP No. of proteins
Lysate SK-Mel 24 Hsp90i/DMSO 50
SK-Mel 28 Hsp90i/DMSO 48
SK-Mel 28 DMSO/SK-Mel 24 + DMSO 61
SK-Mel 28 Hsp90i/SK-Mel 24 Hsp90i 71
In-Cell SK-Mel 24 Hsp90i/DMSO 42
SK-Mel 28 Hsp90i/DMSO 39
SK-Mel 28 DMSO/SK-Mel 24 DMSO 67
SK-Mel 28 Hsp90i/SK-Mel 24 Hsp90i 64
Phospho-TPP
No of
phosphopeptides
In-Cell SK-Mel 24 Hsp90i/DMSO 27
SK-Mel 28 Hsp90i/DMSO 80
SK-Mel 28 DMSO/SK-Mel 24 DMSO 49
SK-Mel 28 Hsp90i/SK-Mel 24 Hsp90i 35
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used for the analysis of the phosphoproteome with the addition of a
TiO2 phosphopeptide enrichment step. Overall, we identified ~7,000
proteins and ~15,500 phosphosites with a localization probability
> 0.75 (Dataset EV2 and EV3). The quality of our data was assessed
by a principal component analysis (PCA) that showed a clear parti-
tion between the two cell lines and the different treatments
employed in this study (Fig EV4C).
In both cell lines, we observed upregulation of Hsp70 upon treat-
ment with XL888 or BRAFi-XL888 (Dataset EV1). Both SK-Mel 28
and SK-Mel 24 are inherently unresponsive to BRAFi (Fig 1A), and
in both cases, the MAPK pathway was activated. In particular, upon
BRAFi treatment SK-Mel 24 cells show upregulation of pERK1
(pY204) and pERK2 (pY187) at phosphoproteome level (Dataset
EV3). Moreover, our data show upregulation at proteome level of
DCLK, a protein involved in tumorigenesis (Hayakawa et al, 2017),
and JAK1, a protein involved in melanoma resistance against BRAFi
(Kim et al, 2015; Dataset EV2). Similarly, in SK-Mel 28 we observed
upregulation of pERK2 (pT185, pY187) and pCRAF (pS296) at phos-
phoproteome level (Dataset EV3), as well as upregulation of CDK2
at proteome level (Dataset EV2). CRAF activation/upregulation has
been previously reported to be involved in mechanisms of resistance
to BRAFi (Montagut et al, 2008) and was also observed in the TPP
experiments (see previous section). The activation of the MAPK
pathway upon BRAFi treatment in both cell lines was confirmed by
Western blot (Fig EV4D).
Inhibition of PAK1, PAK4, and CDK2 overcome the resistance
to XL888
To gain insight into the differential Hsp90i response, we compared
unresponsive (SK-Mel 28) versus sensitive (SK-Mel 24) cells.
However, as the two cell lines are not isogenic, we compared each
cell line (upon treatment with Hsp90i) to its untreated control
(DMSO) and subtracted the upregulated entries of the sensitive cells
from those of the resistant cells (Fig 2B, upper panel). This subtrac-
tive analysis generated a protein list that was analyzed using GOrilla
GO (Eden et al, 2009), which revealed an enrichment of proteins
involved in detoxification, as well as development of pigmentation
(Dataset EV4). Among the upregulated proteins, our analysis
identified nine kinases, three of which were “druggable”: CDK2,
PAK1, and PAK4 (Fig 2B, lower panel). Note that CDK2 and PAK
proteins were also identified in our TPP analyses (see previous
section), further supporting their involvement in the resistance to
XL888.
The same subtractive approach was applied to analyze the phos-
phoproteome in the same setting (Hsp90i/DMSO) and the phospho-
peptides that were uniquely upregulated in SK-Mel 28 were
analyzed by kinase-substrate enrichment analysis (KEA; www.maa
yanlab.net/KEA2; Casado et al, 2013) to predict the most upregu-
lated kinase activities. This bioinformatics analysis predicted CDK2
and GSK3b (P-value < 0.05 and intersected genes > 7) to be the
main kinases involved in the phosphorylation events (Fig 2C).
Overall, the results generated by our proteomics and phosphopro-
teomics platforms combined with TPP analyses provided a number
of potential targets whose inhibition might sensitize SK-Mel 28 to
XL888: CDK2; CDK4; CDK6; CRAF; PAK1, PAK2; PAK4; STAT1; and
GSK3b. This shortlist of potential targets was enriched in CDK and
PAK proteins; CDKs are involved in cell cycle progression and are
often dysregulated in cancer (Malumbres & Barbacid, 2009). Simi-
larly, PAK proteins are generally upregulated in cancer and are
involved in cell survival and angiogenesis, controlling several
processes that are implicated in cancer initiation (Radu et al, 2014).
We assayed the cell viability of our model cell line SK-Mel 28, resis-
tant to XL888 and BRAFi, using specific inhibitors alone and in
combination with Hsp90i against each candidate, and among these,
dinaciclib (CDKi), FRAX597 (PAK1/2/3i), and PF-3758309 (PAK4i;
together with Hsp90i) reduced the cell viability below 50% (Fig 2D).
Targeting CDK2 sensitizes unresponsive cells to both BRAFi and
Hsp90i classes individually and in combination
Considering that our main goal was to design a drug therapy with
high potential to be used in clinics to overcome both BRAFi and
Hsp90i resistances and their combination, we investigated the resis-
tance to BRAFi to decide which of these three drugs (CDK2i, PAK1i,
PAK4i) to analyze further with other cell lines. We exploited the
same subtractive rationale shown previously in Fig 2B; we
compared each cell line upon treatment with BRAFi to its relative
▸Figure 2. Proteomics and phosphoproteomics findings.A Scheme of the different settings (BRAFi = 1 lM dabrafenib; Hsp90i = 200 nM XL888; BRAFi+Hsp90i = 1 lM dabrafenib + 200 nM XL888) employed in this study
after 48 h treatment.
B Venn diagram of the upregulated protein entries in sensitive (SK-Mel 24) and resistant (SK-Mel 28) cells upon treatment with 200 nM XL888 (Hsp90i/DMSO) after
48 h (n = 3). The 240 unique entries for SK-Mel 28 are highlighted in red, among which nine are protein kinases (upper panel). Volcano plot generated by the
comparison between Hsp90i/DMSO in SK-Mel 28 after 48 h (n = 3; lower panel).
C Venn diagram of the upregulated phosphopeptides in sensitive (SK-Mel 24) and resistant (SK-Mel 28) cells upon treatment with 200 nM Hsp90i (Hsp90i/DMSO) at
48 h (n = 3). The 534 unique phosphopeptides for SK-Mel 28 were analyzed by KEA. This bioinformatics analysis predicted CDK2 and GSK3b as upstream active
kinases.
D Effects on the cell viability after 72 h of the inhibitors (and their combinations) that target the potential entries reported in the text for SK-Mel 28 (BRAFi = 1 mM
dabrafenib; Hsp90i = 200 nM XL888; CDK2i = 200 nM dinaciclib; GSK3bi = 2 lM CHIR-99021 HCl; PAK1/2i = 2 lM FRAX597; PAK4i = 2 lM PF-3758309;
STAT1i = 2 lM Fludarabine; CDK4/6i = 2 lM palbociclib). The red arrows highlight the settings were the cell viability falls below 50% upon drug treatment (SD is
plotted; n = 3).
E The same rationale used in (A) was exploited for the proteomics analysis of the effects of BRAFi (1 lM dabrafenib) treatment (upper panel) after 48 h (n = 3). Volcano
plot generated by the comparison between BRAFi/DMSO in SK-Mel 28 after 48 h (n = 3; lower panel).
F The same rationale used in (A) was exploited for the proteomics analysis of BRAFi-Hsp90i combined therapy after 48 h (n = 3).
G Overlap of the downregulated (upper panel) and upregulated (lower panel) kinases at proteomics level unique for SK-Mel 28 in different settings at 48 h (n = 3). In
red, the only shared “druggable” upregulated kinase CDK2 is highlighted.
H Western blot analysis confirms the upregulation of CDK2 in different settings (upper panel). Band intensities were normalized against the mean of b-actins, and lane
1 was used as reference (lower panel).
ª 2018 The Authors Molecular Systems Biology 14: e7858 | 2018 5 of 16
Alireza Azimi et al CDK2i overcomes BRAFi-Hsp90i resistance Molecular Systems Biology
Published online: March 5, 2018 
Out of which 9 kinases
24045118
SK-Mel 24 
Hsp90i / DMSO
SK-Mel 28 
Hsp90i / DMSO
Protein Expression Levels
UPREGULATED
Volcano plot - Protein Expression Levels
SK-Mel 28 + Hsp90i / SK-Mel 28 + DMSO
ADRBK1
RBK2AD
AURK
AXL
CAMK1
B CAMK1G
CAMKK1CAMKK2DAPK1
EPHB2
GRK1
GRK4GRK5
GRK6
KDR LRRK2
MAPKAPK2
MAPKAPK3
MAPKAPK5
MELK
MYLK
MOS
ROS1
STK11
WNK1
ACVR1
ACVR1B
AURKA
BCKDK
BMPR1A
BMPR1B
BMX
BUB1
CAMK1D
CAMK2A
CCNB1
CDC7
CDK6
CDK7
CDK9
CHUK
C
CSNK2A2
EIF2AK1
EIF2AK3
EPHA4
EPHA8
EPHB4
EPHB6
ERBB2
ERBB4
FER
FLT1
FLT4
SK3A
IKBKE
LIMK1
MAP3K14
MAP3K7
MAPK7
K1MAR
MERTK
NEK2
NEK9
NME1
NME2
NTRK1
OXSR1
DK12
PAK4
P
PRKAA1
RKAA2P
PRKACB
PRKCD
PRKCE
PRKCG
PRKCH
PRKCQ
PRKCZ
PRKD1
PRKG2
S6KB2
SIK1
STK10
STK16
STK17B
STK3
TAF1
TBK1
TESK1
TGFBR1
TNIK
TRPM7
TXK
IK3CG
UHMK1 VRK1
WEE1
CDK2534178717
SK-Mel 24  
Hsp90i / DMSO
SK-Mel 28 
Hsp90i / DMSO
Phosphopeptides
UPREGULATED
Prediction of kinase activity in the dataset:
Out of which 10 kinases
17331113
SK-Mel 24 
BRAFi / DMSO
SK-Mel 28 
BRAFi / DMSO
Protein Expression Levels
UPREGULATED
Volcano plot - Protein Expression Levels
SK-Mel 28 + BRAFi / SK-Mel 28 + DMSO
Out of which 12 kinases
15249204
SK-Mel 24 
BRAFi+Hsp90i / DMSO
SK-Mel 28 
BRAFi+Hsp90i / DMSO
Protein Expression Levels
UPREGULATED
Protein Expression Levels
UPREGULATED KINASES UNIQUE FOR SK-Mel 28
3
2
32
4
13
SK-Mel 28 
BRAFi / DMSO
SK-Mel 28 
Hsp90i / DMSO
SK-Mel 28 
BRAFi+Hsp90i / DMSO
D
M
S
O
B
R
A
Fi
H
sp
90
i
B
R
A
Fi
+ 
H
sp
90
i
CDK2
β-actin
SK-Mel 28
36
45
kDa
2
1
0
21 43
R
el
at
iv
e 
in
te
ns
ity
Protein Expression Levels
DOWNREGULATED KINASES UNIQUE FOR SK-Mel 28
2
2
41
7
48
DMSO
BRAFi
Hsp90i
BRAFi
+
 Hsp90i 
Protein expression level 
analysis
Phosphoproteomics
Label-free LC/MS/MS analyses
Protein expression level 
analysis
Phosphoproteomics
Protein expression level 
analysis
Phosphoproteomics
Protein expression level 
analysis
Phosphoproteomics
SK-Mel 24 
(sensitive)
SK-Mel 28 
(resistant)
A B
Upregulated kinase
Downregulated kinase
Druggable kinase unique to 
SK-Mel 28
Not statistical significant / 
not kinase / Common entry 
with Sensitive cells
p=0.05
-L
og
10
 p
-v
al
ue
CDK2
PAK1
PAK4
Log2 Protein ratio
-8 -6 -4 -2 0 8642
0
2
4
6
8
nT=3969
nUP=285nDOWN=275
CDK4
C
Node name p-value # Genes 
intersected (>7)
Gsk3β 0.003 12
CDK2 0.025 8
E
-8 -6 -4 -2 0 8642
0
2
4
6
8
-L
og
10
 p
-v
al
ue
p=0.05
Log2 Protein ratio
CDK2
nT=4054
nUP=204nDOWN=297
Upregulated kinase
Downregulated kinase
Druggable kinase unique to 
SK-Mel 28
Not statistical significant / 
not kinase / Common entry 
with Sensitive cells
F
G
CDK2
ITPKB
FN3K
H
Vi
ab
le
 c
el
ls
 (%
)
0
20
40
60
80
100
120
140
D
M
S
O
B
R
A
Fi
H
sp
90
i
C
D
K
2i
G
S
K
3β
i
G
S
K
3β
i +
 H
sp
90
i
PA
K
1i
 
PA
K
1i
 +
 H
sp
90
i
PA
K
4i
PA
K
4i
 +
 H
sp
90
i
B
R
A
Fi
 +
 H
sp
90
i
D SK-Mel 28
S
TA
T1
i
S
TA
T1
i +
 H
sp
90
i
C
D
K
4/
6i
C
D
K
4/
6i
 +
 H
sp
90
i
C
D
K
2i
 +
 H
sp
90
i
ATM
CDKN2A
SK-Mel 28 
BRAFi / DMSO
SK-Mel 28 
Hsp90i / DMSO
SK-Mel 28 
BRAFi+Hsp90i / DMSO
Figure 2.
6 of 16 Molecular Systems Biology 14: e7858 | 2018 ª 2018 The Authors
Molecular Systems Biology CDK2i overcomes BRAFi-Hsp90i resistance Alireza Azimi et al
Published online: March 5, 2018 
control (DMSO), and we subtracted the upregulated entries of
the sensitive cells from the resistant ones (Fig 2E). Considering the
“druggability” of the kinome, we focused our attention on the
upregulated kinases and a shortlist of ten candidates was generated
(Fig 2E). Again, CDK2 was one of the main druggable targets.
We applied the same subtractive strategy for the analysis of SK-
Mel 28 undergoing the combined treatment BRAFi-Hsp90i/DMSO
and a shortlist of twelve kinases was generated (Fig 2F).
Finally, we compared these shortlists of kinases uniquely down-
regulated in SK-Mel 28 in the three different settings (BRAFi/DMSO,
Hsp90i/DMSO, and BRAFi-Hsp90i/DMSO), and the overlapping
analyses retrieved two proteins involved in regulation of cell cycle
progression, for example, ATM and CDKN2A (Fig 2G, upper panel).
Similar analyses on the upregulated entries revealed three shared
upregulated kinases, for example, CDK2, ITPKB, and FN3K, among
which only CDK2 was “druggable” (Fig 2G, lower panel). Notably,
CDK2 was the only kinase that showed an opposite trend in expres-
sion levels between sensitive and resistant cells upon BRAFi-Hsp90i
treatment (Fig EV4E). Our proteomics data showing the upregula-
tion of CDK2 in SK-Mel 28 in different settings was confirmed by
Western blot analysis (Fig 2H).
Based on these results, we proceeded with further investigations
using dinaciclib. Importantly, this CDK2i is already used in clinical
trials against leukemia (phase III; NCT01580228) and melanoma
(phase II; NCT00937937); hence, its toxicity in patients has been
already assessed favorably (Ghia et al, 2017) and it has high poten-
tial to enter clinics.
Considering that dinaciclib is a pan-CDK inhibitor targeting CDK1,
CDK2, CDK5, and CDK9 (Parry et al, 2010), we assayed SK-Mel 28 cell
viability using a panel of specific CDK inhibitors (Table 2), providing
insight into which kinase would play a major role in the viability of
Hsp90i unresponsive cells. The data clearly show that only the inhibi-
tion of CDK2 has an effect on cell viability, which was potentiated by
the simultaneous treatment with Hsp90i (Fig 3A). Based on these
results, we generated a shRNA doxycycline-inducible knockdown
against CDK2 (Fig 3B). The conditional knockdown of CDK2 sensi-
tizes the cells to Hsp90i (Fig 3C, left panel) and BRAFi (Fig 3C, right
panel) treatments (Fig EV4F), clearly showing that CDK2 is a key
player underlying melanoma resistance to both Hsp90i and BRAFi.
Cell lines resistant to Hsp90i and BRAFi are sensitive to dinaciclib
We assayed the cell viability against dinaciclib (henceforth referred
as CDK2i) in a panel of 11 BRAF-mutated cell lines, including two
PDX-derived cell pairs, obtained before BRAFi treatment,
M026.X1.CL and M029.X1.CL, and after treatment, upon tumor
relapse, M026R.X1.CL and M029R.X1.CL, respectively (Fig 4A;
Possik et al, 2014; Kemper et al, 2016). Dinaciclib was effective
against all the employed cell lines, reducing the cell viability below
50% (Fig 4A). We also evaluated the effect on cell viability when
adding dinaciclib to the combination therapy BRAFi-MEKi (used as
first-line therapy in clinics against melanoma), as well as other
single and combined treatments. Our data show that BRAFi-MEKi-
CDK2i triple treatment (together with CDK2i-Hsp90i combined ther-
apy) is the most effective among the different strategies that were
tested and does not generate any antagonistic effect. Notably, the
BRAFi-MEKi-Hsp90i currently used in clinical trials (NCT02721459)
was unable to reduce the cell viability below the threshold of 50%
in SK-Mel 28 and ESTDAB 37, unlike BRAFi-MEKi-CDK2i or CDK2i-
Hsp90i.
Similarly, CDK2i potentiates the effect of MEKi in two NRAS-
mutated cell lines, SK-Mel 2 and ESTDAB 102 (Fig 4B). The most
potent apoptotic effect is observed in ESTDAB 102 when dinaciclib
is combined with XL888 (Fig 4C).
MITF is the master regulator of Hsp90i resistance through
CDK2 upregulation
To gain insight into the transcription factors that govern the response
to Hsp90i, we conducted a bioinformatics prediction analysis of the
240 significantly upregulated proteomics entries that were unique
to SK-Mel 28, which is unresponsive to Hsp90i treatment (P-
value < 0.05 and fold change ≥ 1.5; Fig 5A). These were analyzed
using ChEA (http://amp.pharm.mssm.edu/Enrichr), a manually
curated database from which the over-representation of transcription
factors in a dataset is predicted (Lachmann et al, 2010). This analy-
sis identified MITF, a transcription factor responsible for melanocyte
differentiation (Cheli et al, 2010), as the only statistically significant
entry (adjusted P-value = 1.73 e7; Dataset EV5). Accordingly, our
data showed upregulation of a number of proteins that control the
transcription of MITF such as pPAK4 (pS474), b-catenin 1 (CTNNB1;
Yun et al, 2015) and ZEB2 (Denecker et al, 2014). Furthermore, we
observed upregulation of a number of known downstream MITF
targets, such as the marker for cell differentiation and pigmentation
DCT (Guyonneau et al, 2004) and CDK2 (Hoek et al, 2008; Fig 5A).
In addition, we observed upregulation of pMITF in our phosphopro-
teomics data. Western blot analysis confirmed upregulation of MITF
and its transcriptional targets DCT and CDK2 as well as downregula-
tion of pERK only upon Hsp90i treatment as compared to the control
(DMSO; Fig 5B). The upregulation of MITF and its transcriptional
target DCT are involved in melanin synthesis, an event that is clearly
visible in the cell pellets (Fig 5B, bottom panel). Based on these
results, we generated a doxycycline-inducible shRNA knockdown
against MITF. Importantly, aside from MITF, we observed remark-
ably reduced expression of its transcriptional target CDK2 (Fig 5C).
The knockdown of MITF sensitized SK-Mel 28 to Hsp90i, but not to
BRAFi treatment, confirming that MITF is essential only for the resis-
tance to Hsp90i treatment (Fig 5D, left panel), but not against BRAFi
(Fig 5D, right panel). We assessed the upregulation of MITF and its
targets DCT and CDK2 in two additional cell lines, A375 and the
PDX-derived M029R.X1.CL. Our Western blot analyses confirmed
clearly the same results observed for SK-Mel 28 (Fig 5E). Cell lines
Table 2. IC50 of the CDKs inhibitors employed in this study.
IC50
CDK1 CDK2 CDK5 CDK9
Ro 3306a 20 nM
K03861b 15.4 nM
Roscovitinec 0.7 lM 0.16 lM
LDC000067d 5.5 lM 2.4 lM 44 nM
aVassilev LT, et al Proc Natl Acad Sci USA 2006, 103(28), 10660–10665.
bAlexander LT, et al ACS Chem Biol 2015, 10(9), 2116–2125.
cMeijer L, et al Eur J Biochem 1997, 243(1-2), 527–536.
dAlbert TK, et al Br J Pharmacol 2014, 171(1), 55–68.
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that are sensitive to Hsp90i show instead a downregulation of the
expression levels of CDK2 (Fig EV4G).
Overall, our data reveal that in our employed model cell line SK-
Mel 28, the inherent resistance to BRAFi is accompanied by activa-
tion of the MAPK pathway, which promotes cell cycle progression
and CDK2 activation. On the other hand, upon Hsp90i treatment,
cell survival is driven by MITF, which sustains CDK2 upregulation,
whilst the MAPK pathway is inactive (Fig 5B and F). Overall, in
both cases, there is a reliance on CDK2.
CDK2 and MITF expression levels correlate in melanoma cell lines
and patients
To further validate our findings, we probed the correlation of MITF
and CDK2 in the publicly available Cancer Cell Line Encyclopedia
(CCLE) containing 935 cell lines. Among the different cancer types,
melanoma-derived cell lines exhibited the highest and most signifi-
cant correlation (Pearson r = 0.8, Padj = 2.4 e
12) between MITF
and CDK2 mRNA expression levels (Fig 6A, Dataset EV6). Of the
melanoma cell lines employed in this study, the highest co-expres-
sion values for MITF and CDK2 were observed in SK-Mel 28.
To corroborate this finding in patient samples, we performed the
same analysis using The Cancer Genome Atlas (TCGA) transcrip-
tomics data. We observed a similar positive correlation between
MITF and CDK2 in melanoma patients (Fig 6B), where melanoma
exhibited the greatest and most significant correlation (Pearson
r = 0.6, Padj = 3.3 e
53) among the available cancers (Dataset EV6).
Furthermore, the correlation between high expression of MITF and
CDK2 was also confirmed by IHC analyses of melanoma patients
(Fig 6C) from the publicly available data from Protein Atlas (www.
proteinatlas.com; Dataset EV7).
Overall, our orthogonal analyses point to CDK2 as a candidate
whose inhibition overcomes inherent resistance to BRAFi and
Hsp90i (driven by MITF) and their combination in melanoma.
Discussion
Considering that the list of driver oncogenes is enriched in protein
kinases (Fleuren et al, 2016) and that there is a growing body of
evidence showing that, in some cases, cancer does not harbor any
genetic mutation (Mack et al, 2014; Parker et al, 2014; Versteeg,
2014), it is imperative to integrate genomics analyses with indepen-
dent and orthogonal proteomics and phosphoproteomics investiga-
tions. Surprisingly, the number of phosphoproteomics studies is still
underrepresented compared to genomics studies.
Here, we performed a multi-layer study on the Hsp90i XL888,
which is used together with BRAFi in clinical trials to treat mela-
noma. We identified the protein targets of Hsp90i in intact cells and
lysate layouts in differentially responsive cell lines using TTP.
Notably, by comparing the thermal stability of the proteome and
phosphoproteome of sensitive and unresponsive cells, we gained
insight into the potential targets (CDK2 and PAKs) that would
explain the different response to XL888 treatment.
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Considering that TPP is biased against membrane proteome, we
pursued complementary unbiased genomewide proteomics and
phosphoproteomics approaches to gain a systems-level understand-
ing of the molecular mechanisms underlying the resistance.
To date, there is no strategy that would be able to predict (i) which
patients would benefit from BRAFi-Hsp90i/BRAFi-MEKi-Hsp90i and
(ii) monitor their response. The only attempt to address these
issues was performed by Rebecca et al (2014), where the authors
set up a targeted proteomics analysis to follow up ~80 proteins,
mainly Hsp90 clients, to monitor patient response. However, their
study presented some limitations as it was performed only on
responsive cell lines (no resistant cell lines were employed in their
workflow); hence, it is not evident from their work which
biomarker can be used with high(er) confidence to distinguish
between responsive and unresponsive cell lines/tumors. In this
regard, in our study we observed that the Hsp90 client AKT1 is
downregulated in both sensitive and unresponsive cells upon
Hsp90i monotherapy and BRAFi-Hsp90i combined therapy
(Fig EV4H); thus, it is not necessarily a valid marker for distin-
guishing which patients will respond. In contrast, CDK2 is the only
kinase that in our data could distinguish between responsive and
unresponsive cell lines, showing different trends in terms of
expression levels (Fig EV4E). Therefore, the valuable shortlist
suggested by Rebecca et al to monitor the therapy response would
need to be further refined including in the analysis additional
settings (e.g., BRAFi-Hsp90i) and resistant cell lines/tumors. This
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refinement will certainly benefit from the in vivo analyses of
patient-derived material generated by the ongoing clinical trial
studies (NCT01657591 and NCT02721459).
We show that the resistance to Hsp90i can be overcome by
targeting different kinases (PAK1, PAK4, and CDK2) in our model
system; however, in-depth analyses reveal that CDK2 is the only
shared upregulated druggable kinase that governs resistance to both
the BRAF and Hsp90 classes of inhibitors and the combination
thereof.
We investigated the mechanisms that govern the CDK2 expression
and in agreement with previous studies (Du et al, 2004), we showed
that CDK2 expression is controlled by MITF, a transcriptional factor
responsible for melanocyte differentiation (Wellbrock & Arozarena,
2015), which has been reported to be controlled by pPAK4 (pS474), b-
catenin 1 (CTNNB1; Yun et al, 2015), and ZEB2 (Denecker et al, 2014).
Importantly, our study sets a remarkable example of cancer plas-
ticity that underlies melanoma primary resistance to drug therapies:
upon BRAFi treatment, the resistance is accompanied by MAPK
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pathway activation, which triggers cell cycle progression and CDK2
activation (Lents et al, 2002). For the first time, it is shown that upon
Hsp90i treatment melanoma upregulates MITF expression to sustain
CDK2 upregulation to survive, while the MAPK pathway is inactive.
The role of MITF in melanoma is controversial as low MITF/AXL
ratio has been related to poor predictive response to targeted therapy
in melanoma (Muller et al, 2014), while others have reported the
involvement of MITF in unresponsiveness to MAPKi and melanoma
progression (Wellbrock & Arozarena, 2015; Smith et al, 2016). Here,
we show that MITF upregulation drives resistance to Hsp90i, but not
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Figure 6. Analysis of CDK2 and MITF expression in CCLE and TGCA databases.
A Plot of CDK2 versus MITF mRNA abundance (log2 TPM) among all melanoma-derived cell lines in the CCLE. Cell lines included in this study have been labeled.
B Plot of CDK2 versus MITF mRNA expression in skin cutaneous melanoma (SKCM) patient samples from TCGA.
C IHC images of matched patient material show strong staining of MITF and CDK2 (co)expression in melanoma tissues (left panels). Normal tissues show low or no
(co)expression in skin tissue (right panels). The data were kindly provided by the Protein Atlas Project publicly available (scale bar is 100 lm) (www.proteinatlas.org).
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to BRAFi, by governing the expression of its transcriptional target
CDK2. We show that this kinase plays a role of paramount impor-
tance in the resistance to both BRAFi and Hsp90i classes of drugs and
their combination (Fig 6C). Our data are in line with Du et al (2004),
identifying CDK2 as a drug target for melanomas.
Considering that MITF is amplified in ~20% of melanomas
(Garraway et al, 2005), no drug is available in clinics that would
directly target this transcription factor, and its expression correlates
with CDK2 in melanoma patients (Fig 6B and C), our work would
suggest a rationale for stratifying patients with MITF amplification/
overexpression and treating them using a dinaciclib-based therapy,
rather than a Hsp90i treatment. This CDK2i is already used in clini-
cal trials (NCT01657591 and NCT02721459), it has been already
shown to be tolerated by patients (Ghia et al, 2017); hence, it has
high potential to be approved for clinical use.
Importantly, considering that the BRAFi-MEKi combination is
already used in clinics and that XL888, as well as dinaciclib, is used
in clinical trials, it seems logical to combine them as they do not
generate any antagonistic effect in our data. Our in vitro results
reveal that the triple treatment, CDK2i-BRAFi-MEKi, as well as the
double-treatment CDK2i-Hsp90i, is effective in all employed cell
lines, unlike BRAFi-Hsp90i/BRAFi-MEKi-Hsp90i used in clinical
trials. Our data thus indicate that these therapies warrant considera-
tion for further in vivo studies.
Materials and Methods
Chemicals and reagents
The drugs employed in this study were as follows: dabrafenib
(ApexBio, B1407-50); XL888 (ApexBio, A4388-25); fludarabine (Sel-
leckchem, S1491); CHIR-99021 HCl (CT99021) (Selleckchem,
S2924); palbociclib (ApexBio, A8316); LDC000067 (ApexBio, B4754-
10); Ro 3306 (ApexBio, A8885-10); roscovitine (ApexBio, A1723-
10); K03861 (Selleckchem, S8100); CHIR-99021 (Selleckchem,
S2924); dinaciclib (Selleckchem, S2768); FRAX597 (Selleckchem,
S7271); PF-3758309 (Selleckchem, S7094); AUY922 (Selleckchem,
S1069); BIIB021 (Selleckchem, S1175); novobiocin (Selleckchem,
S2492); 17-DMAG (Selleckchem, S1142). All the drugs were
dissolved in DMSO (Sigma D2650).
Cell lines and culture conditions
SK-Mel 24, SK-Mel 28, A375, A375DR1 (dabrafenib resistant; 1 lM),
MNT-1 (kindly provided by Dr. Pier Giorgio Natali, Istituto Regina
Elena, Rome, Italy) and MNT-1-DR100 (dabrafenib resistant,
100 nM) cells were grown in Gibco Medium Essential medium
(MEM; ThermoFisher Scientific) supplemented with 10% FBS (15%
for SK-Mel 24), 1% non-essential amino acids, 1% sodium pyru-
vate, 1% penicillin and streptomycin. ESTDAB37 and ESTDAB102
[received from The European Searchable Tumour Line Database
(ESTDAB)], SKMEL2, M026.X1.CL, M026R.X1.CL, M029.X1.CL, and
M029R.X1.CL (post-relapse, resistant to BRAF inhibitor treatment;
Possik et al, 2014; Kemper et al, 2016) were grown in Gibco RPMI
1640 (ThermoFisher Scientific) supplemented with 10% FBS, 1%
non-essential amino acids, 1% sodium pyruvate, 1% penicillin
and streptomycin.
Sample preparation for TPP
Intact cells
SK-Mel 24 and SK-Mel 28 cells were incubated in the presence of
DMSO (control) or drug (100 lM) for 2 h. Cells were harvested,
resuspended in 1.1 ml of HBBS (Gibco) supplemented with 20 mM
MgCl2, 1 mM sodium orthovanadate, 1 tablet of Complete mini
EDTA-free mixture (Roche Applied Science), and one tablet of Phos-
STOP phosphatase inhibitor mixture per 10 ml of lysis buffer (Roche
Applied Science). The cell suspension per cell line (SK-Mel 24 and
SK-Mel 28) and condition (+/ drug) was divided into ten aliquots
of 100 ll and transferred into 0.2-ml PCR tubes. TPP was performed
as previously described (Franken et al, 2015). Briefly, each tube
was heated individually at the different temperatures for 3 min in a
thermal cycler (Applied Biosystems (Foster City, CA)/Life Technolo-
gies) followed by cooling for 3 min at room temperature. Cell were
lysed by freeze and thaw cycles, and the lysates were centrifuged at
20,000 × g for 30 min at 4°C to separate the soluble fractions from
precipitates. The supernatants were transferred to new 0.2-ml
microtubes.
Lysate
SK-Mel 24 and SK-Mel 28 were lysed in lysis buffer (HBBS (Gibco)
supplemented with 20 mM MgCl2, 1 mM sodium orthovanadate, 1
tablet of Complete mini EDTA-free mixture (Roche Applied Science),
and one tablet of PhosSTOP phosphatase inhibitor mixture per
10 ml of lysis buffer (Roche Applied Science)) by freeze and thaw,
and the lysates were centrifuged at 20,000 × g for 30 min at 4°C to
separate the soluble fractions from precipitates. Each cell line’s
supernatant was incubated with either DMSO or 100 lM drug at
room temperature for 30 min. The cell suspension per cell line
(SK-Mel 24 and SK-Mel 28) and condition (+/ drug) was divided
into ten aliquots of 100 ll and transferred into 0.2-ml PCR tubes.
TPP was performed as previously described (Franken et al, 2015).
Each supernatant for cell line (SK-Mel 24 and SK-Mel 28); condi-
tion (+/ drug); and experiment (intact cells/lysate) was reduced
by 2 mM DTT at room temperature for 1 h; alkylated by 4 mM
chloroacetamide for 30 min at room temperature at the dark. A first
enzymatic digestion was performed using Lys-C (1:75 w/w) at 37°C
overnight; a second enzymatic digestion was performed using
trypsin (1:75 w/w) at 37°C overnight. One hundred lg of each
sample was labeled by TMT10plex according to the manufacturer’s
instructions. Samples of each set (10 different temperatures) were
mixed 1:1 (v/v) and cleaned by StrataTM-X-C 33 lm Polymeric
Strong Cation (Phenomenex). The whole procedure was executed in
two biological replicates.
Sample preparation for protein expression levels analysis
SK-Mel 24 and SK-Mel 28 were grown in four different conditions:
in the presence of DMSO (control); 1 lM dabrafenib; 200 nM
XL888; and 1 lM dabrafenib plus XL888200 nM each for 48 h. Cell
pellets were harvested and resuspended in lysis buffer (8 M urea,
100 mM triethylammonium bicarbonate pH 8.5, 1 mM sodium
orthovanadate, 1 tablet of Complete mini EDTA-free mixture
(Roche Applied Science), and one tablet of PhosSTOP phosphatase
inhibitor mixture per 10 ml of lysis buffer (Roche Applied
Science)). Cells were then lysed by 10 rapid passages through a
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23-gauge hypodermic syringe needle and by sonication on ice.
After centrifugation (20,000 × g 30 min at 4°C), the protein
concentration was determined by Bradford assay (Pierce). Proteins
were reduced with 2 mM DTT at room temperature for 1 h, alky-
lated with 4 mM chloroacetamide at room temperature for 30 min
in the dark. A first enzymatic digestion step was performed using
Lys-C at 37°C for 4 h (enzyme/substrate ratio 1:50). Moreover, the
sample was digested overnight at 37°C with trypsin (enzyme/
substrate ratio 1:50). Peptides were desalted by reverse phase
using Waters Sep-Pak 1cc (50 mg) cartridges (WAT054960;
Waters, Milford, MA). The resin was rinsed with ACN and then
equilibrated with 0.6% acetic acid. The samples were loaded and
washed with 0.6% acetic acid and eluted with 80% ACN/0.6%
acetic acid.
Proteomics and phosphoproteomics analyses
Label-free quantification was performed by analyzing the raw data
by MaxQuant (version 1.5.3.30; Cox & Mann, 2008). Andromeda
(Cox et al, 2011) was used to search the MS/MS data against the
UniProt Homo sapiens database (containing canonical and
isoforms_42144 entries downloaded on March 21, 2016) comple-
mented with a list of common contaminants and concatenated with
the reversed version of all sequences. See Appendix for further
details.
To perform a pairwise comparison and filter for those proteins/
phosphopeptides that have a consistent abundance level over three
biological replicates, we applied a two-sample t-test using Perseus
1.5.3.2 (Cox & Mann, 2008). Only those proteins that had a P-
value < 0.05 and an arbitrary cutoff ratio ≥ 1.5 or ≤ 1.5 fold
changes were considered. Only phosphopeptides with a location
probability ≥ 0.75 were considered for statistical analyses.
Proliferation assay (MTS)
CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS)
was purchased from Promega (Cat. no. G3582, Promega, Madison,
WI, USA).
Flow cytometry-based immunostaining and apoptosis/
necrosis analysis
To evaluate the presence of apoptosis/necrosis, we used annexin V-
Fluos (cat. no. 11828681001 Roche) and propidium iodide and
analyzed by NovoCyte flow cytometer (ACEA biosciences, Inc. San
Diego, CA). Between 4 and 10 × 104 cells per well were cultured
and treated with XL888 or dinaciclib for 48–72 h. Then, the cells
were collected and rinsed in PBS, pelleted, and resuspended in incu-
bation buffer (10 mmol/l HEPES/NaOH, pH 7.4, 140 mmol/l NaCl,
5 mmol/l CaCl2) containing 1% annexin V and 1% propidium
iodide (PI) for 10 min.
Plasmid generation and creation of inducible stable cell lines
Inducible shRNA constructs were created by ligating annealed
shRNA-coding oligonucleotides (see Dataset EV8) into an AgeI/
EcoRI double-digested inducible shRNA vector as described previ-
ously (Eshtad et al, 2016). The constructs were validated using
sequencing over the shRNA insertion area. The plasmids, together
with a non-targeting shRNA plasmid (Eshtad et al, 2016), were
packaged into lentiviral particles using a third-generation lentivi-
ral production system described previously (Dull et al, 1998),
using CaCl2-mediated transfection of HEK293T cells, and the
produced lentiviral particles were used to infect SK-Mel 28 cells
together with 0.4 lg/ml hexadimethrine bromide, which were
then selected for successful integration with 1 lg/ml puromycin
over 5 days.
Data and software availability
• The TPP data have been deposited to the ProteomeXchange
Consortium (http://proteomecentral.proteomexchange.org) via
the PRIDE partner repository (Vizcaino et al, 2013) with the
dataset identifier PXD005508.
• The phospho-TPP data have been deposited to the ProteomeX-
change Consortium (http://proteomecentral.proteomexchange.
org) via the PRIDE partner repository (Vizcaino et al, 2013) with
the dataset identifier PXD005547.
• The data were analyzed using an in-house R-package using
similar criteria to those previously described (Savitski et al,
2014). The raw data were analyzed using a similar workflow to
one previously described (Franken et al, 2015) except that each
detected peptide was fit and analyzed individually instead of at a
protein level. See Appendix for further information. The script is
available as “Code EV1”.
• The mass spectrometry proteomics and phosphoproteomics data
have been deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE partner
repository (Vizcaino et al, 2013) with the dataset identifier
PXD005518.
Expanded View for this article is available online.
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